

| alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol |
| Albuterol |
¡Ø ÈÇиí : Salbutamol, 98% (HPLC)
¡Ø µî±Þ : APIs and Bioactives > Adrenergic Agonists
¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 25mg , 100mg
¡Ø ÈÇÐ½Ä : C13H21NO3
¡Ø CAS # : [18559-94-9]
|
| IDENTITY |
|
| CAS Registry #: |
[18559-94-9] |
| MDL Number: |
MFCD00148978 |
| MF: |
C13H21NO3 |
| MW: |
239.31 |
| EINECS: |
242-424-0 |
| BRN: |
6405698 | |
| SPECIFICATIONS & PROPERTIES |
|
| Purity: |
98% (HPLC) |
| Available Spectra: |
LCMS, HPLC |
| Physical Form: |
White to yellow powder |
| Melting Point: |
157-166¡ÆC |
| Long-Term Storage: |
Store long-term at 2-8¡ÆC |
| Shipping: |
Not Regulated for Shipping | | |
BIOLOGICAL INFO |
|
| Application(s): |
Short-acting beta-2-adrenergic receptor agonist |
REVIEWSalbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.
REFERENCES
[1] |
Van Meerbeke, J. P.; Sumner, C. J. (2011). Progress and promise: The current status of spinal muscular atrophy therapeutics. Discovery medicine 12 (65): 291-305. PMID 22031667. |
| [2] |
Carter WJ, Lynch ME (September 1994). Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metab. Clin. Exp. 43 (9): 1119-25. doi:10.1016/0026-0495(94)90054-X. PMID 7916118. |
Risk Description(s)
| R22: |
Harmful if swallowed. |
Safety Description(s)
| S36: |
Wear suitable protective clothing. |


°í¾×°áÁ¦ÀÇ °æ¿ì ¾ÈÀüÀ» À§ÇØ Ä«µå»ç¿¡¼ È®ÀÎÀüȸ¦ µå¸± ¼öµµ ÀÖ½À´Ï´Ù. È®ÀΰúÁ¤¿¡¼ µµ³ Ä«µåÀÇ »ç¿ëÀ̳ª ŸÀÎ ¸íÀÇÀÇ ÁÖ¹®µî Á¤»óÀûÀÎ ÁÖ¹®ÀÌ ¾Æ´Ï¶ó°í ÆÇ´ÜµÉ °æ¿ì ÀÓÀÇ·Î ÁÖ¹®À» º¸·ù ¶Ç´Â Ãë¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹«ÅëÀå ÀÔ±ÝÀº »óǰ ±¸¸Å ´ë±ÝÀº PC¹ðÅ·, ÀÎÅͳݹðÅ·, ÅÚ·¹¹ðÅ· ȤÀº °¡±î¿î ÀºÇà¿¡¼ Á÷Á¢ ÀÔ±ÝÇÏ½Ã¸é µË´Ï´Ù.
ÁÖ¹®½Ã ÀÔ·ÂÇÑ ÀÔ±ÝÀÚ¸í°ú ½ÇÁ¦ÀÔ±ÝÀÚÀÇ ¼º¸íÀÌ ¹Ýµå½Ã ÀÏÄ¡ÇÏ¿©¾ß Çϸç, 7ÀÏ À̳»·Î ÀÔ±ÝÀ» ÇÏ¼Å¾ß Çϸç ÀԱݵÇÁö ¾ÊÀº ÁÖ¹®Àº ÀÚµ¿Ãë¼Ò µË´Ï´Ù.
¹è¼Û ¹æ¹ý : ÅÃ¹è ¹× Á÷³³
¹è¼Û Áö¿ª : Àü±¹
¹è¼Û ºñ¿ë : ÃÑ ±¸¸Å ºñ¿ëÀÌ £Ü100,000 (VATº°µµ) ¹Ì¸¸ÀÏ °æ¿ì ÂøºÒ·Î ¹ß¼Û
¹è¼Û ±â°£ : ±¹»êǰ (3~7ÀÏ), ¼öÀÔǰ (7~14ÀÏ)
¹è¼Û ¾È³»
- »ê°£º®Áö³ª µµ¼Áö¹æÀº º°µµÀÇ Ãß°¡±Ý¾×À» ÁöºÒÇÏ¼Å¾ß ÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.
°í°´´Ô²²¼ ÁÖ¹®ÇϽŠ»óǰÀº ÀÔ±Ý È®ÀÎÈÄ ¹è¼ÛÇØ µå¸³´Ï´Ù. ´Ù¸¸, »óǰÁ¾·ù¿¡ µû¶ó¼ »óǰÀÇ ¹è¼ÛÀÌ ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.


±³È¯ ¹× ¹ÝǰÀÌ °¡´ÉÇÑ °æ¿ì
- »óǰÀ» °ø±Þ ¹ÞÀ¸½Å ³¯·ÎºÎÅÍ 7ÀÏÀ̳»
±³È¯ ¹× ¹ÝǰÀÌ ºÒ°¡´ÉÇÑ °æ¿ì
- °í°´´ÔÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óǰµîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
- Æ÷ÀåÀ» °³ºÀÇÏ¿´°Å³ª Æ÷ÀåÀÌ ÈÑ¼ÕµÇ¾î »óǰ°¡Ä¡°¡ »ó½ÇµÈ °æ¿ì
- ½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇÏ¿© ÀçÆÇ¸Å°¡ °ï¶õÇÒ Á¤µµ·Î »óǰµîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
- ¿Âµµ°ü¸®Ç° ¹× ¼öÀÔǰÀº ¹ÝǰÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ø ÁÖ¹® Ãë¼Ò ¹× ¹ÝǰÀ¸·Î ȯºÒÀ» ¿äûÇÏ½Ç °æ¿ì¿¡´Â E-mail(info@syinnovation.co.kr) »ó´ã¼ºñ½º³ª °í°´¸¸Á·¼¾ÅÍ(070-4829-4101)¸¦ ÅëÇØ ¿äûÇϽøé Ä£ÀýÇÏ°Ô Ã³¸®ÇØ µå¸®°Ú½À´Ï´Ù.